A study published in Clinical Cancer Research found that second primary malignancies (SPMs) after CAR T-cell therapy are statistically comparable to those following other therapies. The FDA issued a warning on SPM risks after CAR T therapy based on data from the FDA Adverse Event Reporting System. However, the study suggests there is no increased risk compared to other standard-of-care therapies. Factors such as the number of prior treatments and follow-up duration may impact SPM risk. More research is needed to understand individual risk levels. The study emphasizes the importance of clear reporting standards for SPMs in clinical trials.
Source link
Study shows CAR T-cell therapy’s risk of second primary malignancies comparable to other treatments
